Alkaptonuria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Alkaptonuria, or Black urine disease, is a rare genetic disorder affecting phenylalanine and tyrosine metabolism. This condition is characterized by homogentisic acid (HGA) accumulation and its oxidized product, benzoquinone acetic acid (BQA), in various tissues and body fluids. These compounds cause darkening of urine when exposed to air and blue-grey coloration of the sclera and ear helix, a joint disease involving both the axial and peripheral joints (ochronotic arthropathy), and other complications such as renal and cardiac problems. The underlying cause of alkaptonuria is the loss-of-function mutations in the HGD gene, which encodes homogentisate 1,2-dioxygenase, an enzyme involved in the breakdown of HGA. The inability to break down HGA leads to its accumulation, causing tissue damage by depositing a melanin-like pigment with a high affinity for connective tissue. This pigment triggers redox reactions and induces free radical production, further damaging the connective tissue. Individuals affected by alkaptonuria may be asymptomatic and unaware of their condition until adulthood. It can be differentiated from other conditions, such as acute intermittent porphyria, rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis.
·
The prevalence of the Alkaptonuria in the
United States is 1 case in one million population.
Thelansis’s “Alkaptonuria Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Alkaptonuria treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Alkaptonuria across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Alkaptonuria Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment